Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 3/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021886 | 0.96 | RAB9A (0.39) | RAB9AMAPTGAASPHK1CYP2C9 | |
| SCHEMBL11275973 | 0.89 | GPR88 (0.38) | RAB9AMAPTGAASPHK1CYP2C9 | |
| SCHEMBL11286172 | 0.89 | GPR88 (0.38) | RAB9AMAPTGAASPHK1CYP2C9 | |
| SCHEMBL11287853 | 0.89 | GPR88 (0.38) | RAB9AMAPTGAASPHK1CYP2C9 | |
| SCHEMBL11270589 | 0.89 | GPR88 (0.38) | RAB9AMAPTGAASPHK1CYP2C9 | |
| SCHEMBL11277030 | 0.89 | GPR88 (0.38) | RAB9AMAPTGAASPHK1CYP2C9 | |
| SCHEMBL11284184 | 0.87 | GPR88 (0.38) | RAB9AMAPTGAASPHK1CYP2C9 | |
| SCHEMBL11058858 | 0.86 | RAB9A (0.39) | RAB9AMAPTGAASPHK1CYP2C9 | |
| SCHEMBL9417019 | 0.86 | LMNA (0.43) | RAB9AMAPTCYP2C9ALDH1A1LMNA | |
| SCHEMBL11284320 | 0.85 | RAB9A (0.48) | RAB9AMAPTGAASPHK1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026021-B2 | Fluorinated heterocycles and their use in liquid-crystal mixtures | MERCK PATENT GMBH (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20050056812-A1 | Fluorinated heterocycles and their use in liquid-crystal mixtures | MERCK PATENT GMBH (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050056812-A1 | Fluorinated heterocycles and their use in liquid-crystal mixtures | CHRM1, SCO2, CHRM2 | RAB9A 2079/4885MAPT 3342/4885GAA 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.